| Company/Division name | Catalent Cell & Gene Therapy |
| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2021 |
| Domestically, the work will be done: | In-house |
| City reshored to: | Rockville |
| State(s) reshored to: | MD |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Plasmid DNA, pDNA |
| What non-domestic negative factors made offshoring less attractive? | Travel cost/time |
| What domestic positive factors made reshoring more attractive? | Skilled workforce availability/training, Under-utilized capacity, Other, import replacement |
